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A B S T R A C T
Deep eutectic solvents (DES) can be formed by bioactive compounds or pharmaceutical ingredients. A
therapeutic DES (THEDES) based on ibuprofen, a non-steroidal anti-inﬂammatory drug (NSAID), and
menthol was synthesized and its thermal behavior was analyzed by differential scanning calorimetry
(DSC). A controlled drug delivery system was developed by impregnating a starch:poly-e-caprolactone
polymeric blend (SPCL 30:70) with the menthol:ibuprofen THEDES in different ratios (10 and 20 wt%),
after supercritical ﬂuid sintering at 20 MPa and 50 C. The morphological characterization of SPCL
matrices impregnated with THEDES was performed by scanning electron microscopy (SEM) and micro-
computed tomography (micro-CT). Drug release studies were carried out in a phosphate buffered saline.
The results obtained provide important clues for the development of carriers for the sustainable delivery
of bioactive compounds.
ã 2015 Elsevier B.V. All rights reserved.
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Deep eutectic solvents (DES) have been presented as alternative
solvents for a variety of applications, similarly to the developments
observed with ionic liquids (ILs) in the early 90’s (Abbott et al.,
2004; Paiva et al., 2014; Pena-Pereira and Namiesnik, 2014). DES
present, however, two major advantages that overcome the limited
applicability of ILs. DES, and particularly natural deep eutectic
solvents (NADES), are produced from naturally occurring mole-
cules and have therefore inherent low toxicity (Dai et al., 2013).
Additionally they are formed by combining two or more
compounds that are solid at room temperature, which upon
mixing at a particular composition become liquid.
The development of therapeutic deep eutectic solvents
(THEDES) is a ﬁeld of research that has not been extensively
explored. Stott and co-workers reported that ibuprofen formed
eutectic mixtures with different terpenes that were shown to* Corresponding author at: 3B’s Research Group—Biomaterials, Biodegradables
and Biomimetics, University of Minho, AvePark, Zona Industrial da Gandra, 4805-
017 Barco, Portugal. Fax: +351 253 510909.
E-mail address: aduarte@dep.uminho.pt (A.R.C. Duarte).
http://dx.doi.org/10.1016/j.ijpharm.2015.06.038
0378-5173/ã 2015 Elsevier B.V. All rights reserved.promote enhanced skin permeation. It has also been reported that
DES can dissolve model drugs, increasing their solubility, perme-
ation and absorption (Stott et al., 1998). The enhancement of the
permeation of THEDES has been demonstrated by Wang et al.
(2014). The permeation of the lidocaine:ibuprofen system can be
ﬁnely tuned depending on the molar ratio of the two components,
allowing the development of tailor-made, transdermal drug
delivery systems (Wang et al., 2014). Tuntarawongsa and
Phaechamud (2012a,b) reported on the preparation of a DES with
therapeutic properties, consisting of a mixture of menthol and
camphor with dissolved ibuprofen. DES dissolved considerable
higher amounts of ibuprofen when compared to water. With the
addition of a polymer, a polymeric eutectic drug delivery system
was formed (Tuntarawongsa and Phaechamud, 2012b). The same
behavior was observed by Morrison et al. (2009) who studied the
solubilisation of benzoic acid, danazol, griseofulvin, AMG517 and
itraconazole in urea:choline chloride and malonic acid:choline
chloride DES. Bica et al. (2012) reported on the synthesis of new
therapeutic ILs, namely tetrabutylphosphonium ibuprofenate and
ephedrinium ibuprofenate and on the controlled release of these
ILs from porous silica particles. The possibility to couple a THEDES
with a second component, particularly a polymer, and to
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future developments in pharmaceutical and biomedical applica-
tions of these systems. The doping of biopolymers with THEDES is a
new strategy for the delivery of the therapeutic agent. Biodegrad-
able polymers made from renewable resources are an important
innovation in materials science (Malafaya et al., 2007; Mano et al.,
2007). Starch-based polymers in particular have been studied for a
wide range of applications including the development of
controlled drug delivery systems (Balmayor et al., 2009; Lu
et al., 2009; Reis et al., 2008; Silva et al., 2004). Their natural origin,
together with their mechanical properties and biocompatibility,
are behind the potential of starch-based materials in the
biomedical ﬁeld (Marques et al., 2002).
The combination of THEDES, biodegradable natural based
polymers, and supercritical carbon dioxide (scCO2) is a viable
alternative for the production of drug delivery systems. The use of
scCO2 for the development of enhanced biomaterials for pharma-
ceutical and/or biomedical applications has been reported in
different reviews (Duarte et al., 2009a,b; Knez et al., 2011; Salerno
and Pascual, 2015; Zhang et al., 2014). CO2 is the most commonly
used solvent at supercritical conditions due to its low critical
parameters (Tc = 31.1 C and Pc = 73.8 bar) and to the fact that it is
environmentally benign, non-toxic, non-ﬂammable, non-corro-
sive, readily available and inexpensive. Supercritical ﬂuid sintering
was proposed by Singh et al. (2010) for the preparation of highly
porous and interconnected structures, under mild conditions. The
supercritical sintering technique, similarly to supercritical ﬂuid
foaming, relies on the plasticizing effect of CO2, which reduces the
glass transition temperature (Tg) of the polymer. In the case of
sintering, polymeric particles are softened and fused together
creating a three dimensional (3D) structure (Alves et al., 2012).
Supercritical ﬂuid sintering is a technique which relies on the
decrease of the Tg of the polymer (Duarte et al., 2013). The
softening of the polymer under a CO2 atmosphere allows the
sintering of the particles, promoting their adhesion while leaving
empty pores inside the formed structure. Supercritical ﬂuid
sintering has been described in the literature for the preparation
of different scaffolds, particularly for tissue engineering, and it is
particularly attractive due to the mild operating conditions, which
allow the processing of thermolabile substances (Bhamidipati
et al., 2013; Singh et al., 2010). The main objective of this work was
the development of a controlled delivery system based on a starch
polymer blend impregnated with menthol:ibuprofen THEDES,
obtained by supercritical ﬂuid sintering.
2. Materials and methods
2.1. Materials
The reagents used in the preparation of THEDES were menthol
(98%, CAS 89-78-1, Sigma) and ibuprofen, which was obtained
from ibuprofen sodium salt (98%, CAS 31121-93-4, Sigma). A
50 mg/mL solution of this compound in distilled water was
prepared, and the pH was adjusted to 1-2 by adding small amounts
of a solution of hydrochloric acid (1 M) (36.5-38%, CAS 764-01-0,
Scharlau). The two compounds react, yielding ibuprofen in its acid
form, and sodium chloride. Ibuprofen is extracted with dichloro-
methane (99.8%, CAS 75-09-2, Fluka) that is subsequently
subjected to drying with sodium sulphate, ﬁltration and evapora-
tion of the solvent under reduced pressure until a ﬁne white
powder is obtained. The purity of the obtained ibuprofen was
accessed by GC and NMR to a value of >98%. The polymer used in
this work was a commercial blend of corn starch (70 wt%) with
poly-e-caprolactone (PCL; 30 wt%), henceforth designated SPCL, in
granular form, obtained from Biocycle. Carbon dioxide (99.998 mol
%) was supplied by Air Liquide. Phosphate buffered saline (PBS)was prepared from Phosphate buffered saline tablets (Sigma) as
indicated. One tablet is dissolved in 200 mL of deionized water,
yielding a 0.01 M phosphate buffer, 0.0027 M potassium chloride,
0.137 M sodium chloride, pH 7.4 solution, at 25 C. All chemicals,
with the exception of ibuprofen, were used without any further
puriﬁcation.
2.2. THEDES preparation
The menthol:ibuprofen THEDES was prepared according to
previous reports (Carriazo et al., 2012; Russ and Konig, 2012; Stott
et al., 1998), in a 3:1 molar ratio eutectic mixture. The compounds
were weighted and mixed. The solid mixture was heated up to
40 C until it became a clear liquid. Following the procedure of Stott
et al., (1998), the mixture was stored at 20 C until further use.
2.3. Characterization
2.3.1. Water content—Karl Fischer titration
The water content of the THEDES was determined by Karl
Fischer titration, using an 831 KF Coulometer with generator
electrode without diaphragm. The water content values given are
an average of at least three measurements.
2.3.2. Thermal properties—differential scanning calorimetry (DSC)
DSC analysis was performed on a Q2000 isothermal differential
calorimeter (TA Instruments, TzeroTM DSC technology). The
samples were packed in a TA aluminum pan. For samples of
menthol and ibuprofen, DSC data were collected between 90 C
and 120 C, at a rate of 10 C/min. In the case of the 3:1 menthol:
ibuprofen mixture, the DSC analysis was performed between
10 C and 120 C, at a rate of 1 C/min.
2.4. Dissolution studies
For the dissolution studies, approximately 65 mg of 3:1
menthol:ibuprofen was weighed and immersed in 20 mL of PBS.
Samples of 0.5 mL were withdrawn at 5, 15, 20, 30, 45 60, 120 and
180 min, 5, 7 and 24 h, and each sample was replaced by an equal
amount of fresh PBS. The dissolution tests were also carried out
with ibuprofen in the solid form. The same mass of ibuprofen
present in 65 mg of THEDES was used, which corresponded to
approximately 20 mg. The samples dissolution was quantiﬁed by
UV–vis spectroscopy at 265 nm in a microplate reader (BIO-TEK,
SYNERGY HT). The results presented are an average of three
measurements. The cumulative mass of drug released was
determined taking into consideration the replacement of aliquots
with fresh medium and the dilution derived from the addition of
fresh buffer.
A calibration curve for ibuprofen (correlation coefﬁcient of
0.99996) was obtained using standards prepared with the
following concentrations: 0 (blank), 0.05, 0.1, 0.2, 0.5 and 1 mg/
mL. A calibration curve for ibuprofen (correlation coefﬁcient of
0.99999) was also built using the same concentrations of 3:1
menthol:ibuprofen.
2.5. Supercritical ﬂuid sintering
SPCL in granular form was milled in an ultra-centrifugal mill
(Retsch, ZM 200). Appropriate amounts of SPCL in powder form
and of THEDES were weighed and mixed to yield SPCL mixtures
with 10 and 20 wt.% of 3:1 menthol:ibuprofen. The mixtures were
homogeneous. SPCL in the same amount as used to prepare SPCL-
THEDES mixtures was used as control. Another control was
prepared by mixing SPCL powder with ibuprofen also in powder
form. In this case, the amount of ibuprofen was the same as used in
Fig. 1. Schematic of the preparation of 3:1 menthol:ibuprofen THEDES. The ﬁnal
mixture is liquid at room temperature.
Fig. 2. DSC thermogram of racemic menthol used in the preparation of 3:1
menthol:ibuprofen THEDES.
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loaded onto a stainless steel mold and were placed in the high-
pressure vessel. The reactor was pre-heated in a thermostatic
water bath at 50 C. CO2 was pressurized with a high pressure
liquid pump (Haskel MCPV-71, USA), until the desired pressure was
reached. The samples were sintered with scCO2 at 20 MPa and
50 C, for 2 h. The vessel was then slowly depressurized and the
sample recovered.
2.6. Morphological characterization
2.6.1. Scanning electron microscopy (SEM)
SEM was used to analyze the surface morphology and the
porosity of the matrices. The observation of the cross-sections of
the samples was done after fracturing the matrix with liquid
nitrogen. All samples were sputter-coated with gold before
analysis. Micrographs were acquired on a SEM JSM-6010LV (JEOL,
Japan).
2.6.2. Micro-computed tomography (micro-CT)
Micro-CT was used to evaluate the porosity and pore size of the
3D structures obtained. The images were acquired on a high-
resolution micro-CT SkyScan 1072 scanner (Skyscan, Belgium)
using a voltage of 40 kV and a current of 248 mA. After image
acquisition the noise was reduced with nRecon software. CT
Analyser1 software (SkyScan, Belgium) was used to obtain
representative data sets of the samples and converting them into
2D images.
2.7. Release studies
SPCL-THEDES matrices were immersed in 20 mL of PBS, at 37 C.
Aliquots of 0.5 mL were withdrawn at predetermined time
intervals and replaced by an equal amount of fresh medium.
Aliquots were analysed by UV–vis spectroscopy, similarly to the
dissolution studies. The pH of each solution was also measured in
order to determine the effect of release on the acidity of the
medium.
3. Results and discussion
3.1. Preparation of THEDES
As referred in Section 2, the 3:1 menthol:ibuprofen THEDES
remained a liquid at room temperature, with no evidence of phase
separation or deposition (Fig. 1).
3.2. Thermal properties
A DSC analysis of the 3:1 menthol:ibuprofen THEDES was
performed, as well as for the individual components. In the
thermogram of menthol (Fig. 2), two asymmetric peaks corre-
sponding to melting are observed, yielding melting temperatures
(Tm) of 29 and 35 C, in good agreement with data from Corvis et al.
(2012). The two melting peaks are result from the presence of two
polymorphs of racemic menthol, a and b (Corvis et al., 2012). The
crystallization temperature (Tc) is observed at 16 C in the ﬁrst scan
(run 1) and in subsequent scans is located at 6 C.
In the thermogram of ibuprofen (Fig. 3), in the ﬁrst heating scan
(run2) melting is observed with Tm of 77 C, which is in good
agreement with the literature (Dudognon et al., 2008). This peak is
no longer observed in subsequent scans, indicating that the sample
did not undergo recrystallization, remaining fully amorphous. This
can be conﬁrmed by the detection of a glass transition, with a glass
transition temperature (Tg) located at 41 C, close to the Tg value
reported in literature (Bras et al., 2008).From the thermograms of 3:1 menthol:ibuprofen, shown in
Fig. 4, it is clear that the thermal behavior of THEDES is different
from the behavior of the individual components.
The only thermal event detected in successive scans is the glass
transition, which occurs with a mid-point temperature at 50.1 C
(Table 1). This presents evidence that the material is fully
amorphous from the moment it is prepared, remaining stable
after successive thermal treatment cycles, provided that maximum
temperature remains below 100 C, at which the sample degrades.
The lowering of Tg provides evidence of interactions established
between menthol and ibuprofen, which make the THEDES behave
like a different entity.
Fig. 3. DSC thermogram of ibuprofen used in the preparation of 3:1 menthol:
ibuprofen THEDES.
Fig. 4. DSC thermogram of 3:1 menthol:ibuprofen THEDES.
Table 1
Experimental data obtained from DSC analysis for menthol, ibuprofen and 3:1
menthol:ibuprofen THEDES (taken at mid-point, in the ﬁrst DSC run).
Sample Tg (C) Tc (C) Tm (C)
Menthol – 16 29, 35
Ibuprofen 41 – 77
3:1 menthol:ibuprofen 50.1 – –
Fig. 5. Dissolution proﬁle of ibuprofen in powder form and in the 3:1 menthol:
ibuprofen THEDES.
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Different studies in the literature report the permeation of
THEDES through a membrane (Marques et al., 2002; Stott et al.,
1998). Nonetheless the dissolution proﬁle of the THEDES in
comparison with that of the active pharmaceutical ingredient (API)
has not been discussed. Differences would be expected as the API is
in different forms, in the THEDES ibuprofen is in the liquid state
while the pure API is in the powder form. It is known that, various
factors affect the dissolution of an API, namely drug crystallinity,
polymorphism, solubility and particle size, among others (Wil-
liams et al., 2013). For this reason it is important to compare the
dissolution proﬁle of ibuprofen, the model NSAID used in this
work, in powder form and in the eutectic mixture, as shown in
Fig. 5. The ﬁgure gives the percentage of drug release, Mt/Minf,
where Mt corresponds to the mass of ibuprofen in solutionmeasured at time t, and Minf is the mass of ibuprofen in solution
upon complete solubilisation.
From Fig. 5 it can be observed that ibuprofen in the THEDES has
a similar dissolution proﬁle than pure ibuprofen. This may indicate
that the interactions established between menthol and ibuprofen
upon THEDES formation are disrupted when the THEDES is in
aqueous solution. The dissolution proﬁles allow the calculation of
the dissolution efﬁciency, which is a parameter conventionally
used to characterize pharmaceutical dosage forms (Costa et al.,
2001). The dissolution efﬁciency is deﬁned as the ratio between
the integral of percentage of drug released until time t and the
integral of 100% drug dissolution at the same time t (Eq. (1)):
Dissolution efficiency ¼
R t
0
Mt
Minf  dtR t
0 1  dt
 100 (1)
After 7 h the dissolution efﬁciency for pure ibuprofen and for
ibuprofen from the THEDES was similar and close to 86%.
3.3. Supercritical sintering
The development of suitable carriers for active agents is an
important ﬁeld of research in pharmaceutical applications. In this
work we have prepared 3D structures of an SPCL polymer blend
doped with THEDES via supercritical ﬂuid sintering. A sample of
SPCL and a sample of SPCL loaded with ibuprofen were used as
control, as stated previously.
The thermal behavior of SPCL has been reported previously and
reveals the presence of a melting peak at 60 C, corresponding to
the PCL part of the blend, while no additional thermal events are
observed in the range 150–200 C (Craveiro et al., 2014). For this
reason, the temperature chosen for supercritical sintering of the
matrices was 50 C.
The 3D structures obtained are highly porous and when these
were impregnated with THEDES no excess liquid was observed on
the surface of the matrices.
3.4. Morphological analysis
The morphological analysis of the matrices prepared was
performed by SEM and micro-CT. Fig. 6 presents the SEM and
micro-CT images of the cross-section cuts of the structures. Micro-
CT analysis allows the visualization of the three cross-sectional
Fig. 6. (A) Scanning electron microscopy images; (B) micro-computed tomography cross-sections of SPCL (B1), SPCL + ibuprofen (B2); SPCL + 10% THEDES (B3), and SPCL + 20%
THEDES (B4).
Fig. 7. Pore size distribution of the matrices prepared using supercritical ﬂuid
sintering.
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anisotropy of the structures.
From the images it can be observed that the presence of the
THEDES enhanced the formation of a more open structure with
higher porosity and interconnectivity. Additionally, micro-CT
allows the quantiﬁcation of the morphological parameters of
the matrices prepared, which are summarized in Table 2. Pore size
distribution was also studied and the results are presented in Fig. 7.
Despite the fact that the average pore size is similar in all
matrices, the values of porosity and interconnectivity present
some differences, and conﬁrm the SEM results showing an increase
of 31% in porosity and 25% in interconnectivity between SPCL and
SPCL impregnated with 20% THEDES. The matrices loaded with the
same mass of ibuprofen (SPCL + ibuprofen, and SPCL + 10% THEDES)
have similar morphological properties. Being a liquid, THEDES
contributes to the aggregation of the polymer particles in larger
agglomerates that will sinter upon exposure to scCO2 and will
contribute to a higher porosity and interconnectivity. This effect is
more pronounced for higher amounts of THEDES; as observed.
These differences may play an important role in the role of the
structure as a controlled drug delivery carrier. The morphological
properties of the 3D architecture, namely parameters such as
porosity and interconnectivity will contribute to the tortuosity of
the system which is a feature that will, on its turn, inﬂuence the
release of the active compounds.
3.5. Release studies
The performance of the matrices prepared was tested in vitro in
PBS, an isotonic solution, for 21 days. Release studies were
conducted and the cumulative mass release of ibuprofen was
recorded, as shown in Fig. 8. The concentration in solution, or theTable 2
Morphological parameters of 3D structures prepared by supercritical ﬂuid sintering.
Porosity (%) Interconnectivity (%)
SPCL 13 3
SPCL + ibuprofen 23 8
SPCL + 10% THEDES 17 7
SPCL + 20% THEDES 44 28cumulative mass of drug released, is higher in the case of
SPCL + 20% THEDES, as expected. It is interesting to notice the
differences observed between the polymeric matrixes loaded with
the same amount of ibuprofen (SPCL + ibuprofen and SPCL + 10%
THEDES). Although the dissolution proﬁle of pure ibuprofen was
similar to the dissolution proﬁle of ibuprofen in THEDES (Fig. 5),
ibuprofen presents a faster release from the polymeric carrier
impregnated with THEDES than from the SPCL + ibuprofen matrix
(Fig. 8).
Fig. 8 shows Mt/Minf as a function of time, which allows a more
objective comparison of the rate of release and the mechanisms
that underlie the release proﬁle. As regards the percentage of
ibuprofen released, SPCL + ibuprofen and SPCL + THEDES matrices
present similar proﬁles, with SPCL + 10% THEDES having a faster
release of ibuprofen to the solution. The morphological properties
of the matrices, especially porosity and interconnectivity, play an
important role in the water uptake of the structures, the swelling
Fig. 8. Percentage of ibuprofen released from SPCL + ibuprofen, SPCL + 10% THEDES
and SPCL + 20% THEDES matrices.
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matrix to the solution (Siepmann and Peppas, 2001). The fact that
THEDES is in the liquid form, together with the higher porosity of
the matrices, may help to understand this behavior. Nonetheless,
matrices loaded with ibuprofen and 10% THEDES have similar
morphological characteristics and SPCL + 10% THEDES has a faster
release rate. On the other hand, for the same time period studied
the sample SPCL + 20% THEDES released 80% of the ibuprofen
loaded. The release of the sample with 20% THEDES did not reach
100% during the time frame evaluated, which may be due to
diffusion constrictions of the active compound from the core of the
matrix to the media.
After 21 days, the pH of the samples was measured and it was
observed that the pH decreased to 7.02 in the case of SPCL (used as
control), to 6.56 in the case of SPCL + ibuprofen (mixture of the two
powders also used as control), to 6.70 for SPCL + 10% THEDES, and
to 6.46 for SPCL + 20% THEDES.
The mathematical modeling of the release of THEDES from the
polymeric matrix can further elucidate the mechanisms governing
the release. Several empirical and semi-empirical mathematical
models have been derived from Fick’s law of diffusion (Costa et al.,
2001; Siepmann and Gopferich, 2001; Siepmann and Peppas,
2001). The Korsmeyer-Peppas model is a semi-empirical model
which can be used to relate the amount of drug released with time
when the release deviates from the purely Fickian diffusion (Costa
et al., 2001; Siepmann and Peppas, 2011).
This model relies, however, on several assumptions that cannot
be disregarded. This model assumes that the diffusion is one
dimensional, the swelling is negligible, the diffusivity is constant
and the release experiments were carried out under sink
conditions, i.e., the equilibrium was not altered throughout the
duration of the experiment (Siepmann and Peppas, 2011). At these
conditions, can be applied to the systems studied:Table 3
Release exponent and kinetic constant of the release systems prepared.
Sample n k R2
SPCL + ibuprofen 0.41 0.099 0.9955
SPCL + 10% THEDES 0.46 0.147 0.9835
SPCL + 20% THEDES 0.46 0.137 0.9960Mt
Minf
¼ Ktn (2)
k is the kinetic constant and n is the release exponent, which is
characteristic of the drug release mechanism. The linearity of this
equation can only be veriﬁed up to 60% of the total amount of drug
Minf. Table 3 presents the values of the parameters calculated.
The correlation coefﬁcient obtained for the ﬁt of the Korsmeyer-
Peppas model to the experimental release data for all three
formulations indicates that this semi-empirical model is able to
accurately predict the mechanism of ibuprofen release from the
SPCL matrix. The release exponent (n), which is nearly 0.45,
indicates that the diffusion of the drug out of the matrices,
considered as cylinders, is the mechanism that governs the release
(Siepmann and Peppas, 2001). SPCL is mostly hydrophobic with
low swelling ability, and therefore this effect was not anticipated.
The values of the kinetics constants calculated (k) for the
different matrices evidence a steeper initial slope for the matrices
loaded with THEDES. For the initial time points the diffusion of
ibuprofen from the liquid THEDES promotes a faster release rate.
Despite the fact that the solubility proﬁle of solid form of ibuprofen
and the liquid form of THEDES give a similar proﬁle (Fig. 5), when
impregnated in a 3D matrix the liquid form presents a faster
diffusion and therefore an enhanced delivery rate. Complementary
information can though be taken from the data obtained.
Depending on the application it is possible to tune the release
proﬁle of the active compound by changing its physical state from
solid to liquid and incorporating it in a polymeric delivery system.
5. Conclusions
In this work we have developed a delivery system for
therapeutic deep eutectic solvents (THEDES), namely for 3:1
menthol:ibuprofen. Supercritical ﬂuid sintering was used to
prepared 3D porous structures impregnated with THEDES. The
results demonstrate that the solubility proﬁles of ibuprofen in
powder form and in THEDES in PBS are similar, nonetheless, when
they are incorporated in a matrix the liquid form has a faster
release proﬁle. The drug release in this system is mostly governed
by diffusion, as expected due to the hydrophobic nature of the
polymer used as carrier. The outcomes of this work prove,
hereafter, the feasibility to couple green technologies for the
development of enhanced biomaterials for pharmaceutical appli-
cations.
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